Evidence map›Paper›PMID 41059234›Full record

ArticleBeyoglu eye journal2025

Comparison of the Depth of the Stromal Demarcation Line and Clinical Outcomes in Corneal Crosslinking Treatment with Hydroxypropyl Methylcellulose-Based and Vitamin E-TPGS-Based Riboflavin Solutions.

Hafize Gokben Ulutas, Ayse Balikci Tufekci

Abstract read
In one paragraph

Article in Beyoglu eye journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hafize Gokben UlutasDepartment of Ophthalmology, University of Health Sciences, Bursa City Hospital, Bursa, Türkiye.
Ayse Balikci TufekciDepartment of Ophthalmology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aims to compare the visual and topographic results and the depth of demarcation line in patients who underwent epithelial-off-cross-linking (CXL) with riboflavin solutions containing D alpha-tocopheryl polyethylene-glycol 1000 succinate (Vitamin E-TPGS) and 1.1% hydroxypropyl methylcellulose (HPMC). Methods: Patients with progressive keratoconus, 26 treated with HPMC (Group 1) and 34 treated with Vitamin E-TPGS (Group 2), were evaluated retrospectively. Best corrected visual acuity, spherical equivalent, refractive cylinder, and corneal topography parameters (keratometry of flat and steep meridians (K1 and K2), maximum keratometry (Kmax), central, thinnest, and apical corneal thickness) at baseline and post-operative follow-up visits were compared (1, 3, 6, and 12 months). Corneal stromal demarcation line depth (DLD) was measured centrally, nasally, and temporally (1.5 mm and 3 mm distance from the center of the cornea) by anterior segment optical coherence tomography at 1 month post-operatively, and changes in endothelial cell density (ECD) at 6 months were compared between the two groups. Results: There was no difference between the two groups in terms of age and gender. The mean DLD was deeper in group 1 (325.95±76.55 µm) than in group 2 (267.94±54.2 µm) (p=0.002). In the 3 Conclusion: HPMC-based riboflavin appears to be associated with a deeper demarcation line than Vitamin E-TPGS-based riboflavin. While a decrease in K values was observed in the earlier period in HPMC, no difference was observed between Vitamin E-TPGS and HPMC at the 12

Indexed as

Crosslinkingdemarcation linekeratoconusvitamin E TPGS-based riboflavin

Identifiers

PMID41059234
PMCPMC12499721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.